What are the main revenue drivers for IDEXX Laboratories?

IDEXX's primary revenue driver is its Companion Animal Group (CAG), which includes diagnostic products and services for veterinarians, such as rapid assay tests, instruments and consumables, and laboratory and consulting services. The Water and Food Diagnostics Groups also contribute to revenue through their respective testing solutions.

How is the company managing its supply chain, given its reliance on single or limited sources for certain products?

IDEXX acknowledges its reliance on single or limited sources for certain key components and instruments. The company actively seeks to extend supply agreements and has historically been successful in ensuring uninterrupted supply. However, they note that there's no assurance of successful extensions on equivalent terms, and potential cost increases or shipment delays are a risk.

What is the company's strategy regarding acquisitions?

IDEXX strategically pursues acquisitions that enhance its existing businesses or create new business areas. Recent acquisitions include Vet Med Lab in Germany and Dr. Bommeli AG in Switzerland, aimed at expanding their veterinary laboratory services and production animal diagnostics capabilities, respectively.

Does IDEXX pay dividends to its shareholders?

No, IDEXX has never paid cash dividends on its common stock. The company expects to reinvest future earnings to fund the development and growth of its business.

IDXX 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong performance for the fiscal year ended December 31, 2004, with total revenue increasing by 15.4% to $549.2 million. This growth was primarily driven by the Companion Animal Group (CAG), which saw a 16.7% revenue increase, bolstered by strong performance in laboratory and consulting services, as well as instruments and consumables. The company's strategic focus on integrated diagnostic solutions for veterinary practices continues to yield positive results, evidenced by increasing adoption of its IDEXX VetLab® suite and digital radiography systems. The company also demonstrated improved profitability, with gross profit increasing by 21.2% and gross profit margin expanding to 50.8% from 48.4% in the prior year. This margin expansion was attributed to productivity improvements, favorable currency exchange rates, and optimized supplier agreements. Operating expenses grew at a controlled rate, leading to a significant 34.4% increase in operating income. IDEXX continues to invest in research and development, focusing on new product innovation and enhancements to existing offerings, positioning itself for sustained growth in the veterinary diagnostics and companion animal health markets.

Key Highlights

1Total revenue grew 15.4% to $549.2 million in 2004, up from $476.0 million in 2003.
2Companion Animal Group (CAG) revenue increased by 16.7% to $448.7 million, driven by laboratory services and instruments/consumables.
3Gross profit increased by 21.2% to $279.0 million, with gross margin improving to 50.8% from 48.4%.
4Operating income saw a significant increase of 34.4% to $108.0 million.
5The company made strategic acquisitions, including Vet Med Lab in Germany and Dr. Bommeli AG in Switzerland, to expand its offerings and geographic reach.
6Research and development expenses were $35.4 million, representing 6.4% of revenue, underscoring a commitment to innovation.
7IDEXX maintains a strong balance sheet with $157.0 million in cash and investments and no significant long-term debt.

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions